Journal of Diagnostics Concepts & Practice >
Lamb-Shaffer syndrome presenting as short stature with delays in motor and language acquisition: a case report and literature review
Received date: 2022-02-05
Online published: 2022-08-17
Objective: To analyze a case of Lamb-Shaffer syndrome(LAMSHF) with short stature and delayed language and motor development as the main manifestation,and summerize data of the disease in data bank for improving the understanding of this disease. Methods: A male child aged 9 year and 3 months with severe short stature and delayed language and motor development admitted to our hospital was analyzed. Their clinical data were collected, and the genomic DNA was extracted from whole blood of the children and their parents for whole exome sequencing and DNA Sanger sequencing verification. Meanwhile, relevant literature was reviewed to analyze the pathogenesis, clinical characteri-stics, diagnosis and therapy and prognosis of LAMSHF. Results: The height of the boy was 108.7 cm [-4.82 standard deviation (SD)], weight was 17.1 kg (<-2.1 SD), body mass index was 14.5 kg/m2 (-1.1 SD), and gross motor and language development 1-year delay. Laboratory test showed the insulin-like growth factor was 74 ng/mL (-2.14 SD), growth hormone challenge test suggested growth hormone and the remaining tests were all normal. Whole exome sequencing revealed that Seq[GRCh37]del(12)(p12.1s; p11.1) involved multiple known pathogenic genes including SOX5, with a copy number deletion of at least 10.4 Mb, and which were not detected before, so the copy number variant was a novel mutation. The mutation was assessed by ACMG guidelines as probable pathogenic (PS2+PM1). Therefore Lamb-Shaffer syndrome was diagnosed. Literature reviewing indicated that 11 LAMSHF-related studies included 1 domestic study and 10 foreign studies, with a total of 75 patients. The diagnosis of LAMSHF depended on genetic testing, and there is no clear genotype-phenotype correlation. The improvement of the patient's intellectual disability depended on rehabilitation treatment. Due to the high risk of epilepsy, ocular signs, and hypotonia in this disease, and the tendency to have tumors, growth hormone should be avoided for treatment of short stature. Patients with this disease currently had a poor prognosis. Conclusions: The boy with LAMSHF carried 12p12.1 deletion, which is the largest deletion and is never reported, presenting severe short stature. Short stature children with abnormal intelligence need to be screened for gene mutation and copy number variation of SOX5, and growth hormone therapy should be avoided due to potential risk of tumorigenesis.
ZHANG Juanjuan, HE Qinyu, YANG Yuanyan, DONG Zhiya, XIAO Yuan, CHEN Lifen, ZHANG Caiping . Lamb-Shaffer syndrome presenting as short stature with delays in motor and language acquisition: a case report and literature review[J]. Journal of Diagnostics Concepts & Practice, 2022 , 21(03) : 336 -342 . DOI: 10.16150/j.1671-2870.2022.03.008
| [1] | Zawerton A, Mignot C, Sigafoos A, et al. Widening of the genetic and clinical spectrum of Lamb-Shaffer syndrome, a neurodevelopmental disorder due to SOX5 haploinsufficiency[J]. Genet Med, 2020, 22(3):524-537. |
| [2] | 中华医学会儿科学分会内分泌遗传代谢学组. 矮身材儿童诊治指南[J]. 中华儿科杂志, 2008, 46(6):428-430. |
| [2] | Endocrine Genetics and Metabolism Group of Pediatrics Branch of Chinese Medical Association. Guidelines for the diagnosis and treatment of short stature children[J]. Chinese Journal of Pediatrics. 2008; 58(6):443-446. |
| [3] | Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology[J]. Genet Med, 2015, 17(5):405-524. |
| [4] | Schanze I, Schanze D, Bacino CA, et al. Haploinsufficiency of SOX5, a member of the SOX (SRY-related HMG-box) family of transcription factors is a cause of intellectual disability[J]. Eur J Med Genet, 2013, 56(2):108-113. |
| [5] | Lamb AN, Rosenfeld JA, Neill NJ, et al. Haploinsufficiency of SOX5 at 12p12.1 is associated with developmental delays with prominent language delay, behavior problems, and mild dysmorphic features[J]. Hum Mutat, 2012, 33(4):728-740. |
| [6] | Fukushi D, Yamada K, Suzuki K, et al. Clinical and genetic characterization of a patient with SOX5 haploinsufficiency caused by a de novo balanced reciprocal translocation[J]. Gene, 2018, 655:65-70. |
| [7] | Lee RW, Bodurtha J, Cohen J, et al. Deletion 12p12 involving SOX5 in two children with developmental delay and dysmorphic features[J]. Pediatr Neurol, 2013, 48(4):317-320. |
| [8] | Quintela I, Barros F, Lago-Leston R, et al. A maternally inherited 16p13.11-p12.3 duplication concomitant with a de novo SOX5 deletion in a male patient with global developmental delay, disruptive and obsessive behaviors and minor dysmorphic features[J]. Am J Med Genet A, 2015, 167(6):1315-1322. |
| [9] | Nesbitt A, Bhoj EJ, McDonald Gibson K, et al. Exome sequencing expands the mechanism of SOX5-associated intellectual disability: A case presentation with review of sox-related disorders[J]. Am J Med Genet A, 2015, 167A(11):2548-2554. |
| [10] | Zech M, Poustka K, Boesch S, et al. SOX5-Null Heterozygous Mutation in a Family with Adult-Onset Hyperkinesia and Behavioral Abnormalities[J]. Case Rep Genet, 2017, 2017:2721615. |
| [11] | Gkirgkinoudis A, Tatsi C, DeWard SJ, et al. A SOX5gene variant as a possible contributor to short stature[J]. Endocrinol Diabetes Metab Case Rep, 2020, 2020:20-0133. |
| [12] | Innella G, Greco D, Carli D, et al. Clinical spectrum and follow-up in six individuals with Lamb-Shaffer syndrome (SOX5)[J]. Am J Med Genet A, 2021, 185(2):608-613. |
| [13] | 曹井贺, 李建伟, 张玉芹, 等. 一例Lamb-Shaffer综合征患者的 SOX5基因变异分析[J]. 中华医学遗传学杂志, 2021, 38(8):765-767. |
| [13] | Cao JH, Li JW, Zhang YQ, et al. Variant analysis of SOX5 gene in a Lamb-Shaffer syndrome family[J]. Chinese Journal of Medical Genetics, 2021, 38(8):765-767. |
| [14] | Schepers GE, Teasdale RD, Koopman P. Twenty pairs of sox: extent, homology, and nomenclature of the mouse and human sox transcription factor gene families[J]. Dev Cell, 2002, 3(2):167-170. |
| [15] | Ikeda T, Zhang J, Chano T, et al. Identification and characterization of the human long form of Sox5 (L-SOX5) gene[J]. Gene, 2002, 298(1):59-68. |
| [16] | Kiselak EA, Shen X, Song J, et al. Transcriptional regulation of an axonemal central apparatus gene, sperm-associated antigen 6, by a SRY-related high mobility group transcription factor, S-SOX5[J]. J Biol Chem, 2010, 285(40):30496-30505. |
| [17] | Wunderle VM, Critcher R, Ashworth A, et al. Cloning and characterization of SOX5, a new member of the human SOX gene family[J]. Genomics, 1996, 36(2):354-358. |
| [18] | Besenbacher S, Sulem P, Helgason A, et al. Multi-nucleotide de novo Mutations in Humans[J]. PLoS Genet, 2016, 12(11):e1006315. |
| [19] | Lu HY, Cui YX, Shi YC, et al. A girl with distinctive features of borderline high blood pressure, short stature, characteristic brachydactyly, and 11.47 Mb deletion in 12p11.21-12p12.2 by oligonucleotide array CGH[J]. Am J Med Genet A, 2009, 149A(10):2321-2323. |
| [20] | Klopocki E, Hennig BP, Dathe K, et al. Deletion and point mutations of PTHLH cause brachydactyly type E[J]. Am J Hum Genet, 2010, 86(3):434-439. |
| [21] | Martinez-Morales PL, Quiroga AC, Barbas JA, et al. SOX5 5 controls cell cycle progression in neural progenitors by interfering with the WNT-beta-catenin pathway[J]. EMBO Rep, 2010, 11(6):466-472. |
| [22] | Shiseki M, Masuda A, Yoshinaga K, et al. Identification of the SOX5 gene as a novel IGH-involved translocation partner in BCL2-negative follicular lymphoma with t(12;14)(p12.2;q32)[J]. Int J Hematol, 2015, 102(5):633-638. |
| [23] | Seifert MB, Olesen MS, Christophersen IE, et al. Genetic variants on chromosomes 7p31 and 12p12 are associated with abnormal atrial electrical activation in patients with early-onset lone atrial fibrillation[J]. Ann Noninvasive Electrocardiol, 2019, 24(6):e12661. |
| [24] | Zhang L, Xu X, Chen Y, et al. Mapping of developmental dysplasia of the hip to two novel regions at 8q23-q24 and 12p12[J]. Exp Ther Med, 2020, 19(4):2799-2803. |
| [25] | Perdomo S, Anantharaman D, Foll M, et al. Genomic analysis of head and neck cancer cases from two high incidence regions[J]. PLoS One, 2018, 13(1):e0191701. |
| [26] | Grant TJ, Mehta AK, Gupta A, et al. STK38L kinase ablation promotes loss of cell viability in a subset of KRAS-dependent pancreatic cancer cell lines[J]. Oncotarget, 2017, 8(45):78556-78572. |
| [27] | Huang H, Shen H, Wang Y, et al. LOH12CR1 is a novel tumor suppressor inhibiting tumor growth through dere-gulation of G1/S checkpoint in human colorectal carcinoma[J]. Curr Mol Med, 2018, 18(1):25-35. |
| [28] | Yeh CN, Chen MH, Chang YC, et al. Over-expression of TNNI3K is associated with early-stage carcinogenesis of cholangiocarcinoma[J]. Mol Carcinog, 2019, 58(2):270-278. |
/
| 〈 |
|
〉 |
